Single User License
INR 444063
Site License
INR 888126
Corporate User License
INR 1161948

Service Tax Additional

select a format
Price

Single User License
USD 6495
Site License
USD 12990
Corporate User License
USD 16995

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


MediPoint: Non-Vascular Stents-Global Analysis Market Forecasts

MediPoint: Non-Vascular Stents-Global Analysis Market Forecasts


  Request for Sample Report

Executive Summary

MediPoint: Non-Vascular Stents-Global Analysis and Market Forecasts

Non-vascular stent technology has evolved over the years such that these devices are routinely used in clinical practice for different indications. Although it is a mature market, both short and long-term complications associated with non-vascular stents continue to persist. This report focuses on four market categories within the non-vascular stent segment, which includes enteral stents (esophageal, gastroduodenal and colonic stents), pancreatic and biliary stents, airways stents and urinary tract stents (ureteral, prostate and urethral stents). The overall non-vascular stent market has been estimated in this report, which covers the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China and India (10MM) up to 2021. The report provides an investigation of unmet needs, future adoption trends and compound annual growth rates (CAGR) for each geography and market segment. In addition, this report presents the current market drivers and barriers which will influence the future market growth of non-vascular stents in the 10MM.

Highlights

Key Questions Answered

What is the current and future non-vascular stent market outlook in the developed and emerging markets? (Q). What trends are affecting the global non-vascular stents market?

Which are the key, high growth markets that stent manufacturers should expand into? (Q). What non-vascular stent segments are growing the fastest?

There are a few significant unmet needs. (Q). What are these unmet needs? (Q). What is the scope for more innovation and what are the end-users looking for in their products?

Will biodegradable stent systems fulfill these unmet needs? (Q). What is physician perception and market outlook of this technology?

What percent of global profits are from emerging markets? (Q). How will this change in the future?

Boston Scientific currently dominates the global non-vascular stents market. (Q). What is their market share in the major global economies and which companies constitute the remainder of the market?

Reasons To Buy

What Physicians Think' quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. In this report you will understand the perceptions of leading physicians and other stakeholders from around the world. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.

1 Table of Contents

1 Table of Contents 7

1.1 List of Tables 13

1.2 List of Figures 18

2 Introduction 22

2.1 Catalyst 23

2.2 Related Reports 23

3 Industry Overview 24

3.1 Overview 24

3.2 Non-Vascular Stenting Indications 25

3.2.1 Enteral Stents 25

3.2.2 Pancreatic and Biliary Stents 26

3.2.3 Airway Stents 27

3.2.4 Urinary Tract Stents 29

3.3 Types of Stents and Clinical Efficacy 30

3.3.1 Enteral Stents 30

3.3.2 Pancreatic and Biliary Stents 34

3.3.3 Airway Stents 36

3.3.4 Urinary Tract Stents 37

3.4 Procedure Trends 37

3.4.1 US 37

3.4.2 5EU 47

3.4.3 Asia-Pacific 56

3.4.4 South America 66

3.5 Market Access 74

3.5.1 Product Adoption 75

3.5.2 Regulation 82

3.5.3 Reimbursement 88

3.6 Regulatory Issues/Recalls (2011-2014) 98

3.6.1 Cordis Corporation Class II Recall of S.M.A.R.T Control Transhepatic Biliary Stent 98

3.7 Mergers, Acquisitions, and Other Deals 99

3.7.1 Medtronic Acquires Covidien 99

3.7.2 Beijing King Health Signs Distribution Agreement With Allium Medical 99

3.7.3 Cordis Acquires Flexible Stenting Solutions 99

3.7.4 Allium Medical Enters Into Distribution Agreement With Meizler UCB Biopharma 99

3.7.5 Gore and ConMed Extend Distribution Agreement 100

3.7.6 Allium Medical Acquires Gardia Medical 100

3.7.7 Flexible Stenting Solutions Raises Funds in Series B Financing 100

3.8 Economic Impact 100

4 Unmet Needs 103

4.1 Addressing the Complications 103

4.1.1 Enteral Stents 103

4.1.2 Pancreatic and Biliary Stents 104

4.1.3 Airway Stents 105

4.1.4 Urinary Tract Stents 105

4.2 Overcoming Stent Design Challenges 106

4.2.1 Stent Shortening 106

4.2.2 Stent Fracture 107

4.2.3 Flexibility 107

4.3 Simplify Delivery Systems 108

4.4 Disconnect Between Industry and Physicians 108

4.5 Indication-Specific Stents 109

4.6 Lack of Long-Term and Comparative Clinical Data 110

4.7 Refocus on Pipeline Products 111

4.8 Lack of Standardization 112

4.9 Cost-Containment 112

4.10 Need for An International Procedure Registry 113

5 Market Opportunity Analysis 115

5.1 Improve Stent Systems 115

5.2 Biodegradable Stents 115

5.3 Drug-Eluting Stents 119

5.4 Radiosensitization 121

5.5 Customized Stents 122

5.6 Emerging Markets 123

6 Market Drivers and Barriers 124

6.1 Driver: Rising Disease Prevalence 124

6.1.1 Cancer 124

6.1.2 Urolithiasis 125

6.2 Driver: Non-Malignant Stenting Applications to Drive the Market 125

6.2.1 Drainage 125

6.2.2 Bariatric Surgery 126

6.2.3 Neoadjuvant Treatment 127

6.2.4 Benign Strictures 128

6.3 Driver: Fully-Covered, Removable Metal Stents To Drive Future Growth 128

6.4 Driver: Preference for Minimally-Invasive Solutions 130

6.5 Driver: Increased Life Expectancy 130

6.6 Driver: Technological Advancements 131

6.7 Driver: Patient Demand and Awareness 132

6.8 Driver: Rising Competition and Innovation 133

6.9 Barrier: Availability of Venture Capital 133

6.10 Barrier: Burden of Rising Regulation 134

6.11 Barrier: Proving Long-Term Efficacy 135

6.12 Barrier: Medical Device Excise Tax 135

7 Competitive Assessment 137

7.1 Gastrointestinal Stents 137

7.1.1 Overview 137

7.1.2 WallFlex (Boston Scientific Corporation) 137

7.1.3 Evolution (Cook Medical) 139

7.1.4 Niti-S (Taewoong Medical) 141

7.1.5 Other Key Marketed Gastrointestinal Stents 144

7.2 Biliary Stents 145

7.2.1 Overview 145

7.2.2 WallFlex Biliary RX (Boston Scientific Corporation) 145

7.2.3 Cotton-Leung (Amsterdam) (Cook Medical) 148

7.2.4 Bonastent (EndoChoice) 149

7.2.5 Other Key Marketed Biliary Stents 151

7.3 Airway Stents 153

7.3.1 Overview 153

7.3.2 Dumon (Novatech) 153

7.3.3 Aero/Aero DV (Merit Endotek) 154

7.3.4 Ultraflex (Boston Scientific Corporation) 156

7.3.5 Other Key Marketed Airway Stents 158

7.4 Urinary Tract Stents 158

7.4.1 Overview 158

7.4.2 Polaris Ultra (Boston Scientific Corporation) 158

7.4.3 InLay Optima (C.R. Bard) 160

7.4.4 Other Key Marketed Urinary Tract Stents 161

8 Clinical Trials to Watch 162

8.1 Overview 162

8.2 Enteral Stents 162

8.3 Pancreatic and Biliary Stents 164

8.4 Airway Stents 165

8.5 Urinary Tract Stents 165

9 Current and Future Players 166

9.1 Trends in Corporate Strategy 166

9.2 Company Profiles 168

9.2.1 Allium Medical 168

9.2.2 Boston Scientific Corporation 170

9.2.3 ConMed 174

9.2.4 Cook Medical 177

9.2.5 C.R. Bard 179

9.2.6 Ella-CS 182

9.2.7 Merit Endotek 184

9.2.8 M.I. Tech 187

9.2.9 Micro-Tech (Nanjing) 188

9.2.10 Medtronic (Covidien) 191

9.2.11 Novatech 193

9.2.12 Olympus 195

9.2.13 Taewoong Medical 198

9.2.14 Xlumena 200

9.2.15 Other Companies 203

10 Market Outlook 205

10.1 Company Market Share 205

10.1.1 US 205

10.1.2 5EU 206

10.1.3 South America 207

10.1.4 Asia-Pacific 208

10.2 By Market Segment 209

10.2.1 Global Overview 209

10.2.2 Enteral Stents 211

10.2.3 Pancreatic and Biliary Stents 212

10.2.4 Airway Stents 214

10.2.5 Urinary Tract Stents 215

10.3 By Geography 217

10.3.1 Global Overview 217

10.3.2 US 219

10.3.3 EU 222

10.3.4 South America 239

10.3.5 Asia-Pacific 242

11 Appendix 254

11.1 Bibliography 254

11.2 Abbreviations 271

11.3 Research Methodology 276

11.3.1 Overview 276

11.3.2 Coverage 276

11.3.3 Secondary Research 276

11.4 Physicians and Specialists Included in this Study 278

11.5 Primary Research 281

11.5.1 Primary Research-Key Opinion Leader Interviews 281

11.5.2 Primary Research-Physician and Industry Interviews 282

11.5.3 Expert Panel Validation 283

11.6 Forecasting Methodology 284

11.7 About the Authors 285

11.7.1 Analysts 285

11.7.2 Global Head of Healthcare 286

11.8 About MediPoint 287

11.9 About GlobalData 287

11.10 Disclaimer 287

1.2 List of Figures

Figure 1: Enteral Stent-Esophageal 25

Figure 2: Biliary Stent 27

Figure 3: Bronchial Stent 28

Figure 4: Prostatic and Urethral Stents 30

Figure 5: Development Timeline for Esophageal Stents 31

Figure 6: Development Timeline for Gastroduodenal Stents 33

Figure 7: Development Timeline for Colorectal Stents 34

Figure 8: Enteral Stenting Procedure Volumes Forecast for the US, 2011-2021 38

Figure 9: Enteral Stenting Procedure Volumes Forecast for the US By Stent Type, 2013 and 2021 39

Figure 10: Pancreatic and Biliary Stenting Procedure Volumes Forecast for the US, 2011-2021 40

Figure 11: Pancreatic and Biliary Stenting Procedure Volumes Forecast for the US By Stent Type, 2013 and 2021 41

Figure 12: Airway Stenting Procedure Volumes Forecast for the US, 2011-2021 42

Figure 13: Airway Stenting Procedure Volumes Forecast for the US By Stent Type, 2013 and 2021 43

Figure 14: Urinary Tract Stenting Procedure Volumes Forecast for the US, 2011-2021 45

Figure 15: Urinary Tract Stenting Procedure Volumes Forecast for the US By Stent Type, 2013 and 2021 46

Figure 16: Enteral Stenting Procedure Volumes Forecast for the 5EU, 2011-2021 47

Figure 17: Enteral Stenting Procedure Volumes Forecast for the 5EU By Stent Type, 2013 and 2021 48

Figure 18: Pancreatic and Biliary Stenting Procedure Volumes Forecast for the 5EU, 2011-2021 49

Figure 19: Pancreatic and Biliary Stenting Procedure Volumes Forecast for the 5EU By Stent Type, 2013 and 2021 50

Figure 20: Airway Stenting Procedure Volumes Forecast for the 5EU, 2011-2021 51

Figure 21: Airway Stenting Procedure Volumes Forecast for the 5EU By Stent Type, 2013 and 2021 52

Figure 22: Urinary Tract Stenting Procedure Volumes Forecast for the 5EU, 2011-2021 54

Figure 23: Urinary Tract Stenting Procedures Forecast for the 5EU By Stent Type, 2013 and 2021 55

Figure 24: Enteral Stenting Procedure Volumes Forecast for APAC, 2011-2021 57

Figure 25: Enteral Stenting Procedure Volumes Forecast for APAC By Stent Type, 2013 and 2021 58

Figure 26: Pancreatic and Biliary Stenting Procedure Volumes Forecast for APAC, 2011-2021 59

Figure 27: Pancreatic and Biliary Stenting Procedure Volumes Forecast for APAC By Stent Type, 2013 and 2021 60

Figure 28: Airway Stenting Procedure Volumes Forecast for APAC, 2011-2021 61

Figure 29: Airway Stenting Procedure Volumes Forecast for APAC By Stent Type, 2013 and 2021 62

Figure 30: Urinary Tract Stenting Procedure Volumes Forecast for APAC, 2011-2021 64

Figure 31: Urinary Tract Stenting Procedures Forecast for APAC By Stent Type, 2013 and 2021 65

Figure 32: Enteral Stenting Procedure Volumes Forecast for South America, 2011-2021 66

Figure 33: Enteral Stenting Procedure Volumes Forecast for South America By Stent Type, 2013 and 2021 67

Figure 34: Pancreatic and Biliary Stenting Procedure Volumes Forecast for South America, 2011-2021 68

Figure 35: Pancreatic and Biliary Stenting Procedure Volumes Forecast for South America By Stent Type, 2013 and 2021 69

Figure 36: Airway Stenting Procedure Volumes Forecast for South America, 2011-2021 70

Figure 37: Airway Stenting Procedure Volumes Forecast for South America By Stent Type, 2013 and 2021 71

Figure 38: Urinary Tract Stenting Procedure Volumes Forecast for South America, 2011-2021 72

Figure 39: Urinary Tract Stenting Procedures Forecast for South America By Stent Type, 2013 and 2021 73

Figure 40: US Non-Vascular Stents Market, By Company Share, 2013 205

Figure 41: 5EU Non-Vascular Stents Market, By Company Share, 2013 207

Figure 42: South American Non-Vascular Stents Market, By Company Share, 2013 208

Figure 43: APAC Non-Vascular Stents Market, By Company Share, 2013 209

Figure 44: Non-Vascular Stents Sales (USD m) Forecast for the 10MM, 2011-2021 210

Figure 45: Enteral Stents Sales (USD m) Forecast for the 10MM, 2011-2021 212

Figure 46: Pancreatic and Biliary Stents Sales (USD m) Forecast for the 10MM, 2011-2021 213

Figure 47: Airway Stents Sales (USD m) Forecast for the 10MM, 2011-2021 215

Figure 48: Urinary Tract Stents Sales (USD m) Forecast for the 10MM, 2011-2021 216

Figure 49: Non-Vascular Stents Sales Forecast for the 10MM, 2011-2021 218

Figure 50: Non-Vascular Stents Sales (USD m) Forecast for the US, 2011-2021 220

Figure 51: US Non-Vascular Stents Market, By Segment, 2013 and 2021 221

Figure 52: Non-Vascular Stents Sales (USD m) Forecast for the EU, 2011-2021 223

Figure 53: Non-Vascular Stents Sales (USD m) Forecast for France, 2011-2021 225

Figure 54: French Non-Vascular Stents Market, 2013 and 2021 226

Figure 55: Non-Vascular Stents Sales (USD m) Forecast for Germany, 2011-2021 228

Figure 56: German Non-Vascular Stents Market, 2013 and 2021 229

Figure 57: Non-Vascular Stents Sales (USD m) Forecast for Italy, 2011-2021 231

Figure 58: Italian Non-Vascular Stents Market, 2013 and 2021 232

Figure 59: Non-Vascular Stents Sales (USD m) Forecast for Spain, 2011-2021 234

Figure 60: Spanish Non-Vascular Stents Market, 2013 and 2021 235

Figure 61: Non-Vascular Stents Sales (USD m) Forecast for the UK, 2011-2021 237

Figure 62: UK Non-Vascular Stents Market, 2013 and 2021 238

Figure 63: Non-Vascular Stent Sales (USD m) Forecast for Brazil, 2011-2021 240

Figure 64: Brazilian Non-Vascular Stents Market, 2013 and 2021 241

Figure 65: Non-Vascular Stents Sales (USD m) Forecast for APAC, 2011-2021 243

Figure 66: Nonvascular Stents Sales (USD m) Forecast for Japan, 2011-2021 244

Figure 67: Japanese Nonvascular Stents Market, 2013 and 2021 246

Figure 68: Non-Vascular Stents Sales (USD m) Forecast for China, 2011-2021 248

Figure 69: Chinese Non-Vascular Stents Market, 2013 and 2021 249

Figure 70: Non-Vascular Stents (USD m) Forecast for India, 2011-2021 251

Figure 71: Indian Non-Vascular Stents Market, 2013 and 2021 253

Figure 72: Non-Vascular Stents-Primary Call Count by Country 282

Figure 73: Non-Vascular Stents-Primary Call Count by Type 283

1.1 List of Tables

Table 1: Ideal Characteristics of a Stent 24

Table 2: Comparison of Silicone and Metal Airway Stents 36

Table 3: Enteral Stenting Procedure Volumes Forecast for the US, 2011-2021 38

Table 4: Pancreatic and Biliary Stents Procedure Volumes Forecast for the US, 2011-2021 40

Table 5: Airway Stenting Procedure Volumes Forecast for the US, 2011-2021 42

Table 6: Urinary Tract Stenting Procedure Volumes Forecast for the US, 2011-2021 44

Table 7: Enteral Stenting Procedure Volumes Forecast for the 5EU, 2011-2021 47

Table 8: Pancreatic and Biliary Stents Procedure Volumes Forecast for the 5EU, 2011-2021 49

Table 9: Airway Stenting Procedure Volumes Forecast for the 5EU, 2011-2021 51

Table 10: Urinary Tract Stenting Procedure Volumes Forecast for the 5EU, 2011-2021 53

Table 11: Enteral Stenting Procedure Volumes Forecast for APAC, 2011-2021 56

Table 12: Pancreatic and Biliary Stents Procedure Volumes Forecast for APAC, 2011-2021 59

Table 13: Airway Stenting Procedure Volumes Forecast for APAC, 2011-2021 61

Table 14: Urinary Tract Stenting Procedure Volumes Forecast for APAC, 2011-2021 63

Table 15: Enteral Stenting Procedure Volumes Forecast for South America, 2011-2021 66

Table 16: Pancreatic and Biliary Stents Procedure Volumes Forecast for South America, 2011-2021 68

Table 17: Airway Stenting Procedure Volumes Forecast for South America, 2011-2021 70

Table 18: Urinary Tract Stenting Procedure Volumes Forecast for South America, 2011-2021 72

Table 19: GPOs in the US and EU 81

Table 20: Regulatory Differences Between the US and EU for Obtaining Approval for Medical Devices 84

Table 21: Medicare National Average Reimbursement Rates for Non-Vascular Stenting Procedures, 2014 90

Table 22: Direct, Indirect, and Intangible Costs of Non-Vascular Stenting 101

Table 23: WallFlex Family Stent Product Portfolio 138

Table 24: WallFlex Stent Family SWOT Analysis 139

Table 25: Evolution Family Stent Product Portfolio 140

Table 26: Evolution Stent Family SWOT Analysis 141

Table 27: Niti-S Family Stent Product Portfolio 142

Table 28: Niti-S Stent Family SWOT Analysis 143

Table 29: Gastrointestinal Stents, Other Key Marketed Products 144

Table 30: WallFlex Biliary RX Stent Product Portfolio 147

Table 31: WallFlex Biliary RX Stent SWOT Analysis 147

Table 32: Cotton-Leung Stent Product Portfolio 149

Table 33: Cotton-Leung Stent SWOT Analysis 149

Table 34: Bonastent Product Portfolio 150

Table 35: Bonastent Stent SWOT Analysis 150

Table 36: Biliary Stents, Other Key Marketed Products 151

Table 37: Dumon Stent Product Portfolio 154

Table 38: Dumon Stent SWOT Analysis 154

Table 39: Aero/Aero DV Stent Product Portfolio 155

Table 40: Aero/Aero DV Stents SWOT Analysis 156

Table 41: Ultraflex Stent Product Portfolio 157

Table 42: Ultraflex Stent SWOT Analysis 157

Table 43: Airway Stents, Other Key Marketed Products 158

Table 44: Polaris Ultra Stent Product Portfolio 159

Table 45: Polaris Ultra Stent SWOT Analysis 159

Table 46: InLay Optima Stent Product Portfolio 160

Table 47: InLay Optima SWOT Analysis 160

Table 48: Urinary Tract Stents, Other Key Marketed Products 161

Table 49: Major Clinical Trials for Enteral Stents 163

Table 50: Major Clinical Trials for Pancreatic and Biliary Stents 164

Table 51: Major Clinical Trial for Airway Stents 165

Table 52: Company Profile-Allium Medical 168

Table 53: Allium Medical's Marketed Non-Vascular Stent Products 169

Table 54: SWOT Analysis-Allium Medical 170

Table 55: Company Profile-Boston Scientific Corporation 171

Table 56: Boston Scientific Corporation's Marketed Non-Vascular Stent Products 173

Table 57: SWOT Analysis-Boston Scientific Corporation 174

Table 58: Company Profile-ConMed 175

Table 59: ConMed, Key Marketed Non-Vascular Stent Products 176

Table 60: SWOT Analysis-ConMed 177

Table 61: Company Profile-Cook Medical 177

Table 62: Cook Medical, Key Marketed Non-Vascular Stent Products 178

Table 63: SWOT Analysis-Cook Medical 179

Table 64: Company Profile-C.R. Bard 180

Table 65: C.R. Bard, Key Marketed Non-Vascular Stent Products 181

Table 66: SWOT Analysis-C.R. Bard 182

Table 67: Company Profile-Ella-CS 182

Table 68: Ella-CS, Key Marketed Non-Vascular Stent Products 183

Table 69: SWOT Analysis-Ella-CS 184

Table 70: Company Profile-Merit Endotek 185

Table 71: Merit Endotek's Key Marketed Non-Vascular Stent Products 186

Table 72: SWOT Analysis-Merit Endotek 187

Table 73: SWOT Analysis-M.I. Tech 188

Table 74: Company Profile-Micro-Tech (Nanjing) 189

Table 75: Micro-Tech (Nanjing), Key Marketed Non- Vascular Stent Products 190

Table 76: SWOT Analysis-Micro-Tech (Nanjing) 191

Table 77: Medtronic (Covidien) Marketed Non-Vascular Stent Products 192

Table 78: SWOT Analysis-Medtronic (Covidien) 193

Table 79: Company Profile-Novatech 194

Table 80: Novatech's Marketed Non-Vascular Stent Products 194

Table 81: SWOT Analysis-Novatech 195

Table 82: Company Profile-Olympus 196

Table 83: Olympus' Key Marketed Non-Vascular Stent Products 197

Table 84: SWOT Analysis-Olympus 197

Table 85: Company Profile-Taewoong Medical 198

Table 86: Taewoong Medical Marketed Products 199

Table 87: SWOT Analysis-Taewoong Medical 200

Table 88: Company Profile-Xlumena 201

Table 89: Xlumena's Key Marketed Non-Vascular Stent Products 201

Table 90: SWOT Analysis-Xlumena 202

Table 91: Other Companies Involved in the Non-Vascular Stents Market, 2014 203

Table 92: Non-Vascular Stents Sales (USD m) Forecast for the 10MM, 2011-2021 210

Table 93: Enteral Stents Sales (USD m) Forecast for the 10MM, 2011-2021 211

Table 94: Pancreatic and Biliary Stents Sales (USD m) Forecast for the 10MM, 2011-2021 213

Table 95: Airway Stents Sales (USD m) Forecast for the 10MM, 2011-2021 214

Table 96: Urinary Tract Stents Sales (USD m) Forecast for the 10MM, 2011-2021 216

Table 97: Non-Vascular Stents Sales (USD m) Forecast for the 10MM, 2011-2021 217

Table 98: Non-Vascular Stents Sales (USD m) Forecast for the US, 2011-2021 219

Table 99: Non-Vascular Stents Sales (USD m) Forecast for the EU, 2011-2021 223

Table 100: Non-Vascular Stents Sales (USD m) Forecast for France, 2011-2021 224

Table 101: Non-Vascular Stents Sales (USD m) Forecast for Germany, 2011-2021 227

Table 102: Non-Vascular Stents Sales (USD m) Forecast for Italy, 2011-2021 230

Table 103: Non-Vascular Stents Sales (USD m) Forecast for Spain, 2011-2021 233

Table 104: Non-Vascular Stents Sales (USD m) Forecast for the UK, 2011-2021 236

Table 105: Non-Vascular Stents Sales (USD m) Forecast for Brazil, 2011-2021 239

Table 106: Non-Vascular Stents Sales (USD m) Forecast for APAC, 2011-2021 242

Table 107: Non-Vascular Stents Sales (USD m) Forecast for Japan, 2011-2021 243

Table 108: Non-Vascular Stents Sales (USD m) Forecast for China, 2011-2021 247

Table 109: Non-Vascular Stents Sales (USD m) Forecast for India, 2011-2021 250

Table 110: Non-Vascular Stents-Primary Call Count by Country 282

Table 111: Non-Vascular Stents-Primary Call Count by Type 283

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Allium Medical

Boston Scientific Corporation

ConMed

Cook Medical

C.R. Bard

Ella-CS

Merit Endotek

M.I. Tech

Micro-Tech (Nanjing)

Medtronic (Covidien)

Novatech

Olympus

Taewoong Medical

Xlumena


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com